Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma

The NovoTTF-100A device emits frequency-tuned alternating electric fields that interfere with tumor cell mitosis. In phase III trial for recurrent glioblastomas, NovoTTF-100A was shown to have equivalent efficacy and less toxicity when compared to Best Physician's Choice (BPC) chemotherapy. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Eric T, Lok, Edwin, Swanson, Kenneth D, Gautam, Shiva, Engelhard, Herbert H, Lieberman, Frank, Taillibert, Sophie, Ram, Zvi, Villano, John L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101750/
https://www.ncbi.nlm.nih.gov/pubmed/24574359
http://dx.doi.org/10.1002/cam4.210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101750/
https://www.ncbi.nlm.nih.gov/pubmed/24574359
http://dx.doi.org/10.1002/cam4.210

Ejemplares similares